U.S. FDA Accepts Bayer’s Supplemental New Drug Application for KERENDIA® (finerenone) to Treat Adults with Chronic Kidney Disease (CKD) Without Diabetes

Go back to U.S. FDA Accepts Bayer’s Supplemental New Drug Application for KERENDIA® (finerenone) to Treat Adults with Chronic Kidney Disease (CKD) Without Diabetes
Bayer Aktiengesellschaft American Depositary Shares (AMEX: BAYRY) Delayed: 12.24 +0.17 (1.41%)
Previous Close $12.07    52 Week High $135.54 
Open $12.13    52 Week Low $94.36 
Day High $12.34    P/E N/A 
Day Low $12.13    EPS $0.00 
Volume 295,925       

Bayer AG (AMEX: BAYZF) Delayed: 49.06 +1.06 (2.21%)
Previous Close $48.00    52 Week High $135.00 
Open $48.00    52 Week Low $94.95 
Day High $49.06    P/E N/A 
Day Low $49.06    EPS $0.00 
Volume 745